In addition, gefitinib and icotinib were approved as first-line treatment in metastatic NSCLC patients harboring EGFR-sensitive mutations because of their phase III, randomized research of the IPASS trial and the CONVINCE trial, respectively (4, 10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.